Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $80 from $77 and keeps a Buy rating on the shares. The firm said they delivered a slight beat this quarter, pointing to continued slow and steady progress in BBS, as the co works improve the drop-off rate, expand the label and enter into new OUS markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $65 from $55 at TD Cowen
- Rhythm Pharmaceuticals Reports Strong Q3 Revenue Growth
- Rhythm Pharmaceuticals reports Q3 EPS (73c), consensus (80c)
- Rhythm lowers FY24 non-GAAP opex view to $245M-$255M from $250M-$270M
- RYTM Upcoming Earnings Report: What to Expect?